[Skip To Content]
[Website of the National Cancer Institute's Technology Transfer Center. Partnering with Industry for Improved Public Health.]
  • Home
  • Collaborative Opportunities
  • Standard Forms and Agreements
  • Technology Transfer Training
  • Resources
  • Intellectual Property

Inhibitor for the Diagnosis and Treatment of Metastatic Cancer

Background:
The National Cancer Institute's Laboratory of Population Genetics is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize screening markers for early diagnosis of metastasis. Advantages of this technology include:
  • Simple PCR-based assay for detecting single nucleotide polymorphisms (SNPs) within the Sipa-1 gene.
  • Method for diagnosing early onset of metastasis with Sipa-1.
  • Sipa-1 as a new therapeutic target for treatment of metastatic cancer.
  • Inhibitors of Sipa-1 are known in the art, they can be easily screened from existing small molecule libraries.
Technology:
This technology results from the identification of a new gene, Sipa-1, as a possible metastasis modifying gene. Further analyses revealed that Sipa-1 expression levels correlate with metastasis. Inhibitors that modulate the Sipa-1 expression and reduce metastasis in animal models have been identified. Additionally, single nucleotide polymorphisms (SNPs) present in the mouse Sipa-1 gene have been identified that, if also present in humans, could serve as the basis for diagnosing cancer and metastasis. The technology is currently in the pre-clinical stage of development. Laboratory data shows single nucleotide polymorphisms (SNPs) within the Sipa-1 gene linked to metastatic disease. Proof of concept results show that inhibition of Sipa-1 reduces metastasis in mouse models.

IP Status:
  • U.S. Provisional Application filed in February, 2005.
  • PCT Application was filed February, 2006.
  • PCT Publication No. WO 2006084027, published October 8, 2006.

Contact Information:
John D. Hewes, Ph.D., NCI Technology Transfer Center
Phone: 301-435-3121
E-mail: Hewesj@mail.nih.gov

Reference:  #494 BW

Updated 10/29/2007

This opportunity is also listed under the following categories:

E-MAIL SERVICE

TTC maintains an e-mail service to notify you of new Collaborative Opportunities. If you would like to receive these emails, please sign up below. If you'd like to unsubscribe you can use this form as well.

Page Last Updated: 12-17-2008